We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Bad medicine?

13 November 2003 By Robert Cyran

The UK biotech has suffered a huge setback from Pfizer’s move to slow development of its main drug. More ominous still is its partner’s request to review licensing terms for the drug. Investors may want to steer clear of Celltech.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)